📊 $IRWD Rips, $GUTS Drops, and $OPEN Pops in Tuesday’s Market

Happy Wednesday, Investors!

Tuesday brought some sharp moves across the board. $IRWD ( ▲ 0.4% ) ripped higher with no news, as speculators swarmed the GI-focused biotech.

$GUTS ( ▲ 12.04% ) slid after Fractyl’s diabetes treatment rollout raised more questions than confidence.

And $OPEN ( ▼ 7.77% ) (6% volume spike) caught attention as traders reacted to a proposed reverse stock split aimed at keeping its Nasdaq spot.

Let’s break it down. 👇

Matthias Schneider
Editor at Analytica Investor

↑ ↓ 1-day change
Market data: Yesterday’s market close

The small-cap stocks showed mixed performance on Tuesday as the Russell 2000 saw a decent gain of 0.5%, while the S&P/TSX Venture Composite Index slipped 1.2%. Major indexes like the NASDAQ Composite surged slightly by 0.6%. Looking at the secondary index data, all three sectors tracked – Energy, Semiconductors, and Biotechnology – showed positive movements, with the S&P 500 Energy Sector leading the pack at a 1.7% increase.

According to the latest news, experts suggest the rally is set to continue, as per the reports by Schwab Network and Seeking Alpha. In terms of industry developments, there seems to be a lot of optimism around IPOs, with Jeff Richards of Notable Capital suggesting a healthy appetite for new stock issues. Furthermore, despite tariffs increasing inflation, it seems that Chinese companies have found ways to avoid these additional costs, as reported by Yahoo Finance. Lastly, small business optimism appears to be on the rise, but concerns over taxes persist, presenting a mixed picture for the small-cap sector.

Please take note of ongoing trade talks, changes in federal regulations, and continually fluctuating market trends which could impact the small-cap sector. Overall, investors should stay vigilant and keep up to date with industry news to make well-informed decisions.

Press Release Pick

📈 Biggest Gainers 

• Ironwood Pharmaceuticals, Inc. ($IRWD NASDAQ) - 36%: 
  Market Cap: 129,310,362
  
  This healthcare firm develops and commercializes gastrointestinal products, notably linaclotide for irritable bowel syndrome and chronic idiopathic constipation treatment. Rationale: There were no available Press Releases.

• Rafael Holdings, Inc. ($RFL NYSE) - 27%: 
  Market Cap: 142,750,800
  
  This company holds interests in early stage pharmaceuticals and commercial real estate, focusing on cancer therapies and property leasing in the US and Israel.
  
  The final results and closing of the rights offering announced in recent PR releases led to a 27% increase in the stock’s price. (1)

• NWTN Inc. ($NWTN NASDAQ) - 26%: 
  Market Cap: 587,321,391
  
  Specializes in green mobility technology, notably smart passenger vehicles featuring AI, autonomous driving, IoT connectivity, and personalized experiences, based in Dubai.
  
  The recent 26% decrease in the stock price was driven by several PR releases of ongoing investigations from various law firms for possible securities fraud violations and consequent investor alerts, prompting shareholders to take note of these concerns. (1, 2, 3,)

• Webull Corporation Incentive Warrant ($BULLZ NASDAQ) - 19%:
  Market Cap: 155,956,866
  
  As a digital investment platform, it offers trading services, wealth distribution, market data, user community, and investor education.

📉 Biggest Losers

• Fractyl Health, Inc. Common Stock ($GUTS NASDAQ) - -25%: 
  Market Cap: 105,789,532
  
  Develops therapies for type 2 diabetes and obesity, focusing on modifying duodenal dysfunction and metabolic hormone function in pancreatic islet cells.
  
  The recent 25% decrease in stock value was significantly driven by the announcement of a Letter of Intent between Fractyl Health and Bariendo to possibly offer Revita® at Bariendo's nationwide bariatric and metabolic endoscopy centers. (1)

• Wellgistics Health, Inc. ($WGRX NASDAQ) - -19%: 
  Market Cap: 102,041,916
  
  This firm distributes pharmaceutical products, provides third-party logistics services, and operates a platform facilitating prescription transfers and clinical concierge services.
  
  The stock's recent 19% decline is directly linked to the announcement that it will join forces with OptiSource, aiming to expand access and drive savings for independent pharmacies; investors likely responded negatively to the potential threats this collaboration could pose on future earnings. (1)

🚀 Biggest Mover

• Opendoor Technologies Inc. ($OPEN NASDAQ) - 85,213,774 shares traded with an average volume of 62,208,355 (6%):
  Market Cap: 439,379,112
  
  This digital platform enables consumers in the United States to buy and sell homes online and provides title insurance and escrow services.
  
  The anticipation surrounding the preliminary proxy filing seeking approval for a discretionary reverse stock split has significantly influenced the recent fluctuations in the stock's trading volume and price. (1)

🏦 Recent & Relevant IPOs

The recent IPO of Blue Water Acquisition Corp. $BLUWU on NASDAQ stands out with its significant market cap of $230,000,000 amongst other small-cap stocks.

• Omada Health ($OMDA) on NASDAQ (2025-06-06). Market Cap: $150,100,000

• 707 Cayman Holdings Limited Ordinary Shares ($JEM) on NASDAQ (2025-06-09). Market Cap: $10,000,000

• Blue Water Acquisition Corp. ($BLUWU) on NASDAQ (2025-06-10). Market Cap: $230,000,000

Post Of The Day

💵 Recent Earnings

Verint Systems Inc. $VRNT ( ▲ 1.46% ) - Provides actionable intelligence solutions focusing on customer engagement optimization, security intelligence, and fraud, risk and compliance.

• Revenue: 300,400,000 vs est. 299,678,549 (0%)
• EPS: 0.83 vs est. 0.79 (5%)
• Market Cap: 4,683,950,035
• Sector, Industry: Information Technology, Software

Dave & Buster's Entertainment, Inc. $PLAY ( ▲ 2.22% ) - Operates entertainment and dining venues featuring games, live sports, and food in North America with 144 locations as of 2022.

• Revenue: 567,700,000 vs est. 564,997,510 (0%)
• EPS: 0.617 vs est. 0.96 (-36%)
• Market Cap: 893,252,295
• Sector, Industry: Communication Services, Entertainment

Despite serving up revenues that were right on cue, Dave & Buster's $PLAY left investors hungry with an unexpected 36% dip in EPS.

👀 Stocks To Add To Your Watchlist

$ZBIO ( ▼ 1.29% ) · NASDAQ Global Select — Zenas BioPharma, Inc. Healthcare/Biotechnology
YTD: +32.519%
Market Cap: $499,500,145

ZBIO is demonstrating volatile yet promising performance, with a remarkable 13.93% increase in share price on 2025-06-06, signaling strong investor interest. This clinical-stage biopharmaceutical company is actively progressing in immunology-based therapies.

Recent substantial insider buying, notably by CEO Leon O Moulder Jr, underscores confidence in its potential. Despite facing litigation issues, the stock's resilience and sector trends hint at underlying strength. Investors with a high-risk tolerance should consider ZBIO for speculative investment, closely monitoring upcoming legal developments and company announcements for potential impact.

$PLAY ( ▲ 2.22% ) · NASDAQ Global Select — Dave & Buster's Entertainment, Inc. Communication Services/Entertainment
YTD: -14.592%
Market Cap: $893,252,295

Dave & Buster's Entertainment, Inc. (PLAY) is demonstrating resilience amidst market volatility, showcased by a recent upward trend in stock price, which soared to $25.87, recording a 5.44% increase prior to the last reported day.

However, Q1 earnings have fallen short of expectations, possibly due to tariff-induced inflation affecting consumer spending. Investors should monitor if PLAY's entertainment-focused business model can sustain growth as it navigates these challenges, particularly with the latest high-volume trading indicating significant investor interest.

$TMCI ( ▲ 0.92% ) · NASDAQ Global Select — Treace Medical Concepts, Inc. Healthcare/Medical - Devices
YTD: -21.601%
Market Cap: $388,123,850

TMCI has demonstrated resilience in the volatile healthcare sector, closing at $6.17 on June 10, up 3.7% with a volume of 294,459. In the midst of legal challenges, the company's stock remains robust, showing a notable recovery from its monthly low of $5.63.

Despite the sector's fluctuations, TMCI's performance, highlighted by a recent 3.7% uplift in stock price, suggests potential for investors seeking growth within the healthcare devices industry. Investors should monitor TMCI's legal developments closely while considering its positive momentum.

$PEPG ( ▼ 1.36% ) · NASDAQ Global Select — PepGen Inc. 
Healthcare/Biotechnology
YTD: -60.212%
Market Cap: $49,081,415

PEPG, presents a speculative opportunity amidst a flurry of legal activity. The biotech firm, focused on oligonucleotide therapeutics for neuromuscular diseases, has seen volatile trading, with a recent price hovering around $1.5 after a significant drop from a high of $19.298.

Notably, insider transactions include 16,000-share acquisitions by key directors at $1.51, suggesting some level of confidence amidst its challenges. Investors should approach with caution, weighing the potential for rebound against ongoing legal risks.

$SFIX ( ▼ 1.05% ) · NASDAQ Global Select — Stitch Fix, Inc. 
Consumer Cyclical/Apparel - Retail
YTD: +9.611%
Market Cap: $616,936,883

SFIX recently outpaced quarterly revenue estimates, signaling potential resilience amidst market shifts. Despite a challenging tariff environment affecting consumer spending, SFIX's strategic positioning in the Apparel - Retail sector shows promise, with a notable uptick in stock volume and a recovering price trend over the last month.

As investors navigate inflation concerns and sector fluctuation, SFIX's recent performance could offer an intriguing value proposition, especially considering its progression from a quarterly loss narrower than expected.

That’s it for this episode!

Thank you for taking the time to read today’s email! Your support is what allows me to send out this newsletter for free every week. 

Disclaimer: This newsletter is for informational purposes only and contains forward-looking statements that involve risks and uncertainties. Investor Insights Systems does not provide financial advice—please consult a licensed advisor before making investment decisions.